首頁 > 市場調查報告書 > 醫療設備

體外診斷生技設備

市場調查報告書

商品編碼

1917710

數位PCR市場－2026年至2031年預測

Digital PCR Market - Forecast from 2026 to 2031

出版日期: 2026年01月02日 | 出版商:

Knowledge Sourcing Intelligence | 英文 151 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

數位PCR市場預計將從2025年的981,865,000美元成長到2031年的2,151,540,000美元，複合年成長率為13.97%。

數位PCR (dPCR) 市場代表分子診斷和生命科學研究領域的一項重大技術進步，其精確度和絕對定量能力遠超傳統PCR方法。 dPCR透過將核酸樣本分割成數千個獨立的反應，無需標準曲線即可對目標DNA或RNA分子進行精確計數。這種向絕對定量模式轉移正在推動dPCR在需要高靈敏度和高精度的應用領域中得到廣泛應用，例如低頻突變檢測、拷貝數變異分析以及下一代定序結果的檢驗。腫瘤學、感染疾病監測和前沿研究領域對精確基因分析的需求不斷成長，以及技術的持續進步，都推動了dPCR市場的擴張。

市場成長的主要驅動力是全球癌症和感染疾病率的不斷上升，這使得對高靈敏度和高特異性診斷工具的需求日益成長。在腫瘤領域，數位PCR（dPCR）尤其適用於檢測罕見突變、監測微量殘存疾病（MRD）以及透過液態生物檢體評估治療效果。 dPCR能夠從血液樣本中精確量化腫瘤DNA，為患者後續觀察提供了微創方法。同樣，在感染疾病診斷方面，dPCR在檢測低病毒量、精確量化病原體水平以及區分密切相關的病毒株方面具有卓越的靈敏度。隨著臨床對可靠定量數據以指導治療決策的需求日益成長，dPCR正從研究工具發展成為精準醫療工作流程中不可或缺的一部分。

在數位PCR（dPCR）領域，液滴數位PCR（ddPCR）技術可望佔據市場主導地位。此方法利用油包水乳液系統將樣本分割成數萬個奈米升級液滴，每個液滴都可作為獨立的PCR微反應器。 ddPCR的主要優點包括：分割精度高、對複雜樣本中存在的PCR抑制劑具有優異的耐受性，以及絕對定量方面的卓越準確性。這些特性使其特別適用於具有挑戰性的臨床應用，例如檢測循環腫瘤DNA中的罕見突變和精確測量病毒量。整合式、易於使用的ddPCR系統的商業化，在推動這項先進技術從核心研究機構走向臨床診斷實驗室方面發揮了關鍵作用。

臨床診斷領域是數位PCR (dPCR) 的主要且快速成長的應用領域。這一成長得益於dPCR相比定量PCR (qPCR) 具有更高的準確性、可重複性和靈敏度。 dPCR正擴大應用於非侵入性產前檢測 (NIPT)、腫瘤生物標記檢驗以及難以培養或微量病原體的檢測。個人化醫療的趨勢以及對能夠從有限或具有挑戰性的樣本類型中提供可靠結果的穩健檢測方法的需求，正在加速診斷測試的開發及其在常規臨床應用中的整合。

同時，基因工程和基因組學研究的不斷擴展為數位PCR（dPCR）技術的應用創造了有利環境。在學術研究和生物製藥領域，dPCR對於需要絕對定量分析的應用領域至關重要，例如檢驗基因編輯結果（如CRISPR-Cas9）、表徵基因治療中的病毒載體滴度以及進行精確的基因表現分析。該技術無需外部校準即可提供明確的拷貝數數據，使其成為生物製造和治療藥物開發中關鍵品管流程的黃金標準方法。基因組學研發投入的不斷增加以及細胞和基因治療的進步，正在持續推動對這些高精度分析工具的需求。

從區域來看，北美預計將繼續保持在主導地位。這主要得益於該地區先進的醫療基礎設施、許多大型生物技術和製藥公司的集中佈局，以及對基因組研究的大量投資。此外，該地區擁有許多先進診斷實驗室，這些實驗室積極採用創新技術，也進一步推動了市場成長。精準醫療的蓬勃發展，以及公共和私營部門對癌症和感染疾病研究的大量投入，共同建構了一個有利於dPCR技術開發和臨床應用的強大生態系統。

競爭格局主要由成熟的生命科學儀器供應商和專業的分子診斷公司主導。主要參與企業的競爭優勢體現在儀器的通量、靈敏度和易用性，以及包含專有試劑和分析軟體的整合工作流程的開發。策略重點領域包括：拓展經臨床檢驗的檢測項目，提高自動化程度以簡化高通量環境下的工作流程，以及與診斷實驗室和生物製藥公司合作，共同開發針對特定應用的解決方案。持續創新則著重於提升多重偵測能力、降低單樣本成本，以及改善資料分析流程，進而簡化臨床使用者的解讀。

總之，數位PCR市場正從一項專業研究技術轉型為一項用於先進分子診斷的平台技術。其成長與臨床和研究環境中對絕對定量分析日益成長的需求密切相關，與傳統方法相比，數位PCR在準確性和靈敏度方面具有顯著優勢。未來市場趨勢將受到以下因素的影響：進一步融入常規臨床流程、開發標準化診斷檢測方法以及持續創新以提高可及性和通量。隨著精準醫療和數據驅動醫療的日益普及，數位PCR有望在疾病檢測和監測以及個人化治療策略的推進中發揮越來越重要的作用。

本報告的主要優勢

深入分析：提供對主要和新興地區的深入市場洞察，重點關注客戶群、政府政策和社會經濟因素、消費者偏好、垂直行業及其他細分市場。
競爭格局：了解全球主要參與企業的策略舉措，並了解透過正確的策略實現市場滲透的潛力。
市場促進因素與未來趨勢：探索市場促進因素和關鍵趨勢及其對未來市場發展的影響。
可操作的建議：利用這些見解，在快速變化的環境中製定策略決策，開發新的業務流和收入來源。
受眾廣泛：對Start-Ups、研究機構、顧問公司、中小企業和大型企業都很有用且經濟實惠。

以下是一些公司如何使用這份報告的範例

產業與市場分析、機會評估、產品需求預測、打入市場策略、地理擴張、資本投資決策、法規結構及影響、新產品開發、競爭情報

報告範圍：

2021-2025年實際數據及2026-2031年預測數據
成長機會、挑戰、供應鏈前景、法規結構與趨勢分析
競爭定位、策略和市場佔有率分析
按業務板塊和地區分類的收入和預測評估，包括國家/地區
公司概況（策略、產品、財務資訊）、重大發展等。

The digital PCR (dPCR) market represents a significant technological advancement in molecular diagnostics and life science research, offering a level of precision and absolute quantification beyond traditional PCR methods. By partitioning a nucleic acid sample into thousands of individual reactions, dPCR enables the precise counting of target DNA or RNA molecules without the need for a standard curve. This paradigm shift towards absolute quantification is driving adoption in applications requiring high sensitivity and accuracy, including low-abundance mutation detection, copy number variation analysis, and validation of next-generation sequencing results. The market's expansion is fueled by the growing demand for precise genetic analysis in oncology, infectious disease monitoring, and advanced research, supported by continuous technological refinement.

A primary driver for market growth is the increasing prevalence of cancers and infectious diseases globally, which necessitates highly sensitive and specific diagnostic tools. In oncology, dPCR is particularly valuable for detecting rare mutations, monitoring minimal residual disease (MRD), and evaluating treatment response through liquid biopsy applications. Its ability to precisely quantify tumor DNA from a blood sample provides a less invasive method for longitudinal patient monitoring. Similarly, in infectious disease diagnostics, dPCR offers superior sensitivity for detecting low viral loads, quantifying pathogen levels with high accuracy, and distinguishing closely related strains. The clinical need for reliable, quantitative data to guide therapeutic decisions is elevating dPCR from a research tool to an integral component of precision medicine workflows.

Within the dPCR landscape, droplet digital PCR (ddPCR) technology is anticipated to hold a dominant market position. This method utilizes a water-oil emulsion system to partition samples into tens of thousands of nanoliter-sized droplets, each functioning as an independent PCR micro-reactor. The key advantages of ddPCR include its high degree of partitioning, robust resistance to PCR inhibitors present in complex samples, and exceptional precision for absolute quantification. These attributes make it especially suitable for challenging clinical applications such as detecting rare mutations in circulating tumor DNA or accurately measuring viral load. The commercialization of integrated, user-friendly ddPCR systems has been instrumental in translating this advanced technology from core research facilities into clinical diagnostic laboratories.

The clinical diagnostics segment represents a major and rapidly growing application area for dPCR. This growth is driven by the technology's superior accuracy, reproducibility, and sensitivity compared to quantitative PCR (qPCR). dPCR is increasingly employed for non-invasive prenatal testing (NIPT), oncology biomarker validation, and the detection of pathogens that are difficult to culture or present at very low concentrations. The trend toward personalized medicine and the need for robust assays that can deliver reliable results from limited or challenging sample types are accelerating its integration into diagnostic test development and routine clinical use.

Concurrently, the expanding scope of genetic engineering and genomic research is fostering a conducive environment for dPCR adoption. In academic and biopharmaceutical research, dPCR is essential for applications requiring absolute quantification, such as validating gene editing outcomes (e.g., CRISPR-Cas9), characterizing viral vector titers in gene therapy, and performing precise gene expression analysis. The technology's ability to provide unambiguous, copy-number data without external calibration makes it a gold-standard method for critical quality control steps in biomanufacturing and therapeutic development. The rising investment in genomic research and the development of cell and gene therapies are creating sustained demand for these high-precision analytical tools.

Geographically, North America is anticipated to maintain a leadership position in the dPCR market. This is attributed to the region's advanced healthcare infrastructure, high concentration of leading biotechnology and pharmaceutical companies, and substantial investment in genomic research. The presence of a sophisticated network of diagnostic laboratories that are early adopters of innovative technologies further supports market growth. A strong culture of precision medicine, coupled with significant research funding from both public and private sectors for cancer and infectious disease studies, creates a robust ecosystem for the development and clinical application of dPCR technologies.

The competitive landscape features established life science tool providers and specialized molecular diagnostics companies. Key players compete on the basis of instrument throughput, sensitivity, ease-of-use, and the development of integrated workflows that include proprietary reagents and analysis software. Strategic focus areas include expanding the menu of clinically validated assays, enhancing automation to streamline workflow in high-throughput settings, and forming partnerships with diagnostic labs and biopharmaceutical firms to co-develop application-specific solutions. Ongoing innovation is directed at improving multiplexing capabilities, reducing cost per sample, and enhancing data analysis pipelines to simplify interpretation for clinical users.

In conclusion, the digital PCR market is transitioning from a specialized research technology to a cornerstone of advanced molecular diagnostics. Its growth is fundamentally linked to the increasing demand for absolute quantification in both clinical and research settings, where its precision and sensitivity offer tangible advantages over conventional methods. The future trajectory of the market will be shaped by further integration into routine clinical pathways, the development of standardized diagnostic assays, and continued innovation to improve accessibility and throughput. As the emphasis on precise, data-driven healthcare intensifies, dPCR is poised to play an increasingly critical role in disease detection, monitoring, and the advancement of personalized therapeutic strategies.

Key Benefits of this Report:

Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

Historical data from 2021 to 2025 & forecast data from 2026 to 2031
Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
Competitive Positioning, Strategies, and Market Share Analysis
Revenue Growth and Forecast Assessment of segments and regions including countries
Company Profiling (Strategies, Products, Financial Information), and Key Developments among others.

Digital PCR Market Segmentation

By Technology
Droplet Digital PCR
Chip Based Digital PCR
Beaming Digital PCR
By Application
Clinical Diagnostics
Forensic and Others
Research
By Product Type
Digital PCR Systems
Consumables and Reagents
Software and Services
By End-User
Pharmaceuticals and Biotechnology Industries
Clinical Diagnostic Laboratories
Universities
Others
By Geography
North America
USA
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
Germany
France
United Kingdom
Spain
Others
Middle East and Africa
Saudi Arabia
UAE
Others
Asia Pacific
China
India
Japan
South Korea
Indonesia
Thailand
Others

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation

3. BUSINESS LANDSCAPE

3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter's Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. DIGITAL PCR MARKET BY TECHNOLOGY

5.1. Introduction
5.2. Droplet Digital PCR
5.3. Chip Based Digital PCR
5.4. Beaming Digital PCR

6. DIGITAL PCR MARKET BY APPLICATION

6.1. Introduction
6.2. Clinical Diagnostics
6.3. Forensic and Others
6.4. Research

7. DIGITAL PCR MARKET BY PRODUCT TYPE

7.1. Introduction
7.2. Digital PCR Systems
7.3. Consumables and Reagents
7.4. Software and Services

8. DIGITAL PCR MARKET BY END-USER

8.1. Introduction
8.2. Pharmaceuticals and Biotechnology Industries
8.3. Clinical Diagnostic Laboratories
8.4. Universities
8.5. Others

9. DIGITAL PCR MARKET BY GEOGRAPHY

9.1. Introduction
9.2. North America
- 9.2.1. USA
- 9.2.2. Canada
- 9.2.3. Mexico
9.3. South America
- 9.3.1. Brazil
- 9.3.2. Argentina
- 9.3.3. Others
9.4. Europe
- 9.4.1. Germany
- 9.4.2. France
- 9.4.3. United Kingdom
- 9.4.4. Spain
- 9.4.5. Others
9.5. Middle East and Africa
- 9.5.1. Saudi Arabia
- 9.5.2. UAE
- 9.5.3. Others
9.6. Asia Pacific
- 9.6.1. China
- 9.6.2. India
- 9.6.3. Japan
- 9.6.4. South Korea
- 9.6.5. Indonesia
- 9.6.6. Thailand
- 9.6.7. Others